1673001

Travoprost

United States Pharmacopeia (USP) Reference Standard

• Synonyme(s) : Travoprost solution
• Formule empirique (notation de Hill): C₂₆H₃₅F₃O₆
• Numéro CAS: 157283-68-6
• Poids moléculaire : 500.55
• Code UNSPSC : 41116107
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical primary standard
• Famille d'API: travoprost
• Fabricant/nom de marque: USP
• Application(s): pharmaceutical (small molecule)
• Format: neat
• Température de stockage: −20°C
• InChI: 1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
• Clé InChI: MKPLKVHSHYCHOC-AHTXBMBWSA-N

Description

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

• Innovative eye drop applications: Travoprost has been incorporated into engineered lipoprotein nanoparticles, showcasing a novel method for drug delivery aimed at enhancing therapeutic efficacy in ocular treatments, particularly for conditions like glaucoma and ocular hypertension (Fukuda et al., 2024).
• Prostaglandin analogs in glaucoma treatment: The effectiveness and safety of benzalkonium chloride-preserved travoprost eye drops have been critically evaluated, providing insights into their impact on ocular health, particularly on conjunctival goblet cells, which are vital for maintaining eye surface health in glaucoma patients (Nagstrup, 2023).
• Travoprost liquid nanocrystals: Research into travoprost liquid nanocrystals has demonstrated their potential as a significant advancement in glaucoma therapy, offering improved delivery mechanisms and potentially greater efficacy in reducing intraocular pressure (El-Gendy et al., 2023).
• Cerebrospinal fluid reabsorption: Studies on prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa reveal new roles for travoprost in physiological processes beyond ocular applications, indicating potential new therapeutic pathways (Pedler et al., 2021).

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Pictogrammes: GHS02,GHS07
• Mention d'avertissement: Danger
• Mentions de danger: H225,H319
• Conseils de prudence: P210 - P233 - P240 - P241 - P242 - P305 + P351 + P338
• Classification des risques: Eye Irrit. 2 - Flam. Liq. 2
• Code de la classe de stockage: 3 - Flammable liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): 55.4 °F
• Point d'éclair (°C): 13 °C